207 related articles for article (PubMed ID: 18443273)
41. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation.
Gray JX; McMillen L; Mollee P; Paul S; Lane S; Bird R; Gill D; Saal R; Marlton P
Leuk Res; 2012 Apr; 36(4):453-8. PubMed ID: 21967832
[TBL] [Abstract][Full Text] [Related]
42. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
Chen JS; Hsiao CC; Sheen JM; Cheng CN
Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
[TBL] [Abstract][Full Text] [Related]
43. Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia.
Iwasaki T; Sugisaki C; Nagata K; Takagi K; Takagi A; Kojima T; Ito M; Nakamura S; Naoe T; Murate T
Pathol Int; 2007 Oct; 57(10):645-51. PubMed ID: 17803653
[TBL] [Abstract][Full Text] [Related]
44. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse.
Mashima K; Oh I; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Fujiwara SI; Hatano K; Sato K; Omine K; Muroi K; Kanda Y
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e521-e527. PubMed ID: 30181104
[TBL] [Abstract][Full Text] [Related]
45. Wilms' tumor-1 transcript in peripheral blood helps diagnose acute myeloid leukemia and myelodysplastic syndrome in patients with pancytopenia.
Yamauchi T; Matsuda Y; Takai M; Tasaki T; Hosono N; Negoro E; Ikegaya S; Takagi K; Kishi S; Yoshida A; Urasaki Y; Ueda T
Anticancer Res; 2012 Oct; 32(10):4479-83. PubMed ID: 23060576
[TBL] [Abstract][Full Text] [Related]
46. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
47. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
[TBL] [Abstract][Full Text] [Related]
48. Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia.
Osborne D; Frost L; Tobal K; Liu Yin JA
Bone Marrow Transplant; 2005 Jul; 36(1):67-70. PubMed ID: 15908982
[TBL] [Abstract][Full Text] [Related]
49. The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients.
Mitrovic M; Kostic T; Virijevic M; Karan-Djurasevic T; Suvajdzic Vukovic N; Pavlovic S; Tosic N
Int J Lab Hematol; 2020 Feb; 42(1):82-87. PubMed ID: 31830382
[TBL] [Abstract][Full Text] [Related]
50. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?
Bader P; Niemeyer C; Weber G; Coliva T; Rossi V; Kreyenberg H; Gerecke A; Biondi A
Eur J Haematol; 2004 Jul; 73(1):25-8. PubMed ID: 15182334
[TBL] [Abstract][Full Text] [Related]
51. WT1 monitoring in core binding factor AML: comparison with specific chimeric products.
Lasa A; Carricondo M; Estivill C; Bussaglia E; Gich I; Brunet S; Aventin A; Sierra J; Nomdedéu JF
Leuk Res; 2009 Dec; 33(12):1643-9. PubMed ID: 19427034
[TBL] [Abstract][Full Text] [Related]
52. Wilms' tumor 1 (WT1) gene in hematopoiesis: a surrogate marker of cell proliferation as a possible mechanism of action?
Olszewski M; Huang W; Chou PM; Duerst R; Kletzel M
Cytotherapy; 2005; 7(1):57-61. PubMed ID: 16040384
[TBL] [Abstract][Full Text] [Related]
53. Assessment of WT1 Expression as a Marker of Treatment Outcome in Karyotype Normal Acute Myeloid Leukemia Patients in Pakistan.
Ahmed ZA; Shaikh MS; Moatter T
J Coll Physicians Surg Pak; 2016 May; 26(5):441-2. PubMed ID: 27225156
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of WT1 expression at diagnosis and end of induction in Egyptian adult acute myeloid leukemia patients.
Mossallam GI; Abdel Hamid TM; Mahmoud HK
Hematology; 2013 Mar; 18(2):69-73. PubMed ID: 23394625
[TBL] [Abstract][Full Text] [Related]
55. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.
Nomdedéu JF; Hoyos M; Carricondo M; Bussaglia E; Estivill C; Esteve J; Tormo M; Duarte R; Salamero O; de Llano MP; García A; Bargay J; Heras I; Martí-Tutusaus JM; Llorente A; Ribera JM; Gallardo D; Aventin A; Brunet S; Sierra J;
Leukemia; 2013 Nov; 27(11):2157-64. PubMed ID: 23584566
[TBL] [Abstract][Full Text] [Related]
56. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
57. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
Al-Mawali A; Gillis D; Lewis I
Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
[TBL] [Abstract][Full Text] [Related]
58. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
[TBL] [Abstract][Full Text] [Related]
59. The association of level of reduction of Wilms' tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients.
Shibasaki Y; Seki Y; Tanaka T; Miyakoshi S; Fuse K; Kozakai T; Kobayashi H; Ushiki T; Abe T; Yano T; Moriyama M; Kuroha T; Isahai N; Takizawa J; Narita M; Koyama S; Furukawa T; Sone H; Masuko M
Leuk Res; 2015 Jun; 39(6):667-71. PubMed ID: 25890432
[TBL] [Abstract][Full Text] [Related]
60. Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases.
Weisser M; Haferlach C; Haferlach T; Schnittger S
Cancer Genet Cytogenet; 2007 Aug; 177(1):64-9. PubMed ID: 17693194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
